哪里想瘦打哪里！FDA批准Kythera注射药剂上市在即

你才双下巴，你妻女都双下巴！其实质爱美之心人皆有之。如果说赘肉是每一个决心保有完美相貌的“妹纸”或“汉纸”的背叛，那么一个喜感十足的双下巴算得是这些人的世间仇敌了。每一分钟，世界各地都有人为自己的一张大饼脸而感到世间，虽然保有一个肉感十足的双下巴捏上来是才行有肉感的，但是还是有很多人的心理素质使其无法承受一个双下巴之重。您可千万别痴，这甚至已经催生显露一个庞大的产品。根据旧金山皮肤外科手术Association的实地调查深入研究辨识，68%的旧金山人对自己的双下巴表示了“厌倦”之情。而迫切需要，最近Kythera新公司向FDA审批了其专门剿灭双下巴的瘦身服用双管抑制剂ATX-101。这种抑制剂完成了许多“胖纸”梦寐以求的功能，哪里想瘦打哪里，算得是定点减肥。不要以为这种近乎任性的抑制剂只是一个痴话，在FDA下属的皮肤和眼科抑制剂局长会的无记名投票里，专家学者可是以17：0的超高得票一致赞同其该新公司。或许是因为这些专家学者里也有很多不堪双下巴之苦吧。FDA也将原计划于年末内的5年末13日之前对其作显露最后决定。如果一切顺利的话，Kythera新公司原计划于年末内下半年将该商品该新公司，分析方法专业人士原订这一抑制剂的年销售额将最多3亿美元之多。随着瘦身抑制剂产品的日趋增大，Kythera新公司算得是下了一步好棋。新公司于上次以8400万美元的定价从其前合作伙伴拜耳手里归还给了这种抑制剂的全部平等权利。而Kythera新公司也决心便是为冀望在瘦身抑制剂产品里攻城拔寨。就在上个年末，Kythera新公司和Actelion新公司定下价值2700万美元的合作协议，联合开发设计一种失利过的促炎症抑制剂，而这种抑制剂被认为或许联合开发显露一种治疗脱发的抑制剂。详细英文引述：Kythera ($KYTH) won the unanimous support of an FDA advisory panel for its fat-busting injection, rolling toward approval with a first-of-its-kind treatment.The agency's independent Dermatologic and Ophthalmic Drugs Advisory Committee voted 17-0 that the drug's benefits outweighed its risks for patients looking to reduce submental fat, or double chin. The FDA is not required to follow its panels' votes, though it most commonly does, and the agency has promised to make a final decision on the injection by May 13. If all goes according to plan, Kythera plans to launch the drug, ATX-101, in the second half of this year.The biotech's shares he more than tripled since it pulled off a $73 million IPO in 2012, rising steadily as investors bet ATX-101 can carve out a space on the aesthetic market and potentially lure a Big Pharma acquirer. Kythera is pitching the injection as a much-needed nonsurgical option for double chin reduction, citing an American Society for Dermatologic Surgery survey that estimates 68% of Americans are "bothered" by submental fat.Kythera regained full rights to ATX-101's potential last year, orchestrating an $84 million deal to buy out ex-partner Bayer. And the drug, a synthetic version of the fat-blasting deoxycholic acid, could bring in more than $300 million a year once approved, Leerink yst Seamus Fernandez has said."This milestone demonstrates our commitment to developing first-in-class aesthetic products through a focus on scientific rigor and innovation," Kythera CEO Keith Leonard said in a statement. "At Kythera, we remain focused on investing in novel treatments that will allow aesthetic physicians to better meet the needs of their patients."Kythera is also focused on raising some cash now that it has a likely approval ahead. The biotech filed for a $125 million offering as soon as the market closed on Monday. Its share price was down several points at the end of the day.Beyond its top prospect, Kythera is working to build out a pipeline of aesthetic medicines. Last month, the California biotech signed a $27 million deal with Actelion ($ATLN) to get its hands on a once-failed anti-inflammatory medicine that could he a future as a treatment for hair loss.